Company Short-Term Debts: COSCIENS Biopharma Inc. (CSCI)

Graphic logo of COSCIENS Biopharma Inc. (CSCI)

COSCIENS Biopharma Inc. (CSCI) maintains a monopoly position within the oncology and neurology therapy niche, enabling the company to exercise pricing power for its premium drugs. The business leverages advanced peptide engineering to combat rare endocrine pathologies. Following the integration of a private biotech firm, COSCIENS Biopharma Inc. (CSCI) focused on developing its own research portfolio, with the standalone debt metric standing at 0.00. This price chart below details the price action of this asset.

CSCI (COSCIENS Biopharma) Company Short-Term Debts history from 08/10/2024 to 09/14/2025

CSCI (COSCIENS Bio): analytical breakdowns and indicator data

- price and consensus price forecast:
Stock Price COSCIENS Biopharma|CSCI - Consensus Target
- market capitalization data:
Market Capitalization COSCIENS Biopharma Inc.|CSCI - Company Buyout Price
- book capitalization data:
Book Value per Share COSCIENS Biopharma|CSCI - Book Capitalization|Market Value to Book Value Ratio cosciensbio.com|CSCI - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Capital COSCIENS Biopharma Inc.|CSCI - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio COSCIENS Biopharma Inc.|CSCI - Company Aggregate Indebtedness|Debts to Book Capitalization COSCIENS Biopharma Inc.|CSCI - Long-Term Debt|Company Short-Term Debts COSCIENS Biopharma
Analysis of all company metrics:COSCIENS Biopharma, CSCI
Product sample of cosciensbio.com

COSCIENS Biopharma Inc. maintains a strong position in the rare endocrinology pathology segment due to high-precision diagnostics and drug safety. An analysis of current borrowings reflects obligations maturing within one year, allowing for an assessment of the balance between liquidity and the risk of underinvesting in R&D, which is critical for preserving the brand's scientific reputation over the long term.

Competitors of COSCIENS Biopharma Inc. (CSCI)

VRTX: Company Short-Term Debts|ALNY - Company Current Liabilities|Insmed Inc - Company Short-Term Debts|United Therapeutics Inc. (UTHR) - Short-Term Debt Volume|BMRN (BioMarin Pharmaceutical) - Company Short-Term Debts|Company Short-Term Debts BBIO|Company Short-Term Debt BGM Group Ltd (BGM)|Company Short-Term Debt Cogent Biosciences Inc (COGT)|Company Short-Term Debts XERS|KROS - Short-Term Debt Volume|Company Current Liabilities Arcturus Therapeutics|ETON - Current Liabilities|Company Short-Term Debts KMDA|Fulcrum Therapeutics Inc (FULC) - Short-Term Debt|Company Short-Term Debts Abeona Therapeutics, Inc. (ABEO)|Company Short-Term Indebtedness Mereo BioPharma Group PLC (MREO)|Protalix BioTherapeutics (PLX) - Company Current Liabilities|Company Short-Term Loans and Borrowings PLRX (pliantrx.com)|Applied Therapeutics (APLT) - Company Short-Term Debt|Current Liabilities Rein Therapeutics Inc. RNTX|Company Short-Term Debts Gelteq Limited Inc (GELS)|AYTU - Company Short-Term Loans and Borrowings|CMMB: Company Short-Term Debts|SRXH (SRx Health Solutions) - Company Short-Term Debts|PLRZ - Company Short-Term Debt|Company Short-Term Loans and Borrowings AEZS|Company Short-Term Debt CYTH (CTD Holdings)|Company Current Liabilities inozyme.com (INZY)|Company Short-Term Debts RPHM (Reneo Pharmaceuticals)